Skip to content
Screener

Dianthus Therapeutics DNTH Personnel And Related Costs — General And Administrative Expense

Other product segments

Share Based Compensation Expense
$5.75M
Other Costs
$2.65M+37.0%

Similar metrics at other companies

Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — General And Administrative Expense
$859K-9.3%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%
Beam Therapeutics logo
BEAMEmployee Related Expenses — General And Administrative Expense
$11.95M+14.5%
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
MapLight Therapeutics, Inc. logo
MPLTEmployee Related — General And Administrative Expense
$6.99M+239%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total research and development expenses34,52827,003
General and administrative expenses:
Stock-based compensation expense5,7542,840
Personnel and related costs4,0612,561
Other costs2,6531,936
Total general and administrative expenses12,4687,337
Other income, net5,6993,666
Net loss$(40,834)$(29,511)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's personnel and related costs — general and administrative expense?
Dianthus Therapeutics (DNTH) reported personnel and related costs — general and administrative expense of $4.06M in Q1 2026.
How has Dianthus Therapeutics's personnel and related costs — general and administrative expense changed year-over-year?
Dianthus Therapeutics's personnel and related costs — general and administrative expense increased by 58.6% year-over-year, from $2.56M to $4.06M.
What does personnel and related costs — general and administrative expense mean?
This metric captures the personnel-related expenses, including salaries and benefits, for employees working in non-research functions such as executive management, finance, legal, and human resources. It serves as a measure of the company's operational overhead and the cost of supporting the corporate infrastructure required to sustain business activities. Tracking this metric allows stakeholders to evaluate the efficiency of the company's administrative support structure relative to its growth stage.

Ask your AI about Dianthus Therapeutics's personnel and related costs — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude